

# CHANGE HEALTHCARE

FIRST QUARTER FISCAL 2021 EARNINGS CONFERENCE CALL



# Legal

## **FORWARD LOOKING STATEMENT:**

This presentation contains “forward-looking statements” within the meaning of federal securities laws. Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including, but not limited to, our second quarter fiscal 2021 guidance, the supplemental information and assumptions regarding fiscal 2021, the potential length and impact of COVID-19 and descriptions of our business plans and strategies. These statements often include words such as “anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “estimate,” “target,” “project,” “should,” “could,” “would,” “may,” “will,” “forecast,” “outlook,” “potential,” “continues,” “seeks,” “predicts,” and the negatives of these words and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties, including, but not limited to, the uncertainty around the length and severity of the COVID-19 pandemic; the ongoing impact of the COVID-19 pandemic on our operations and financial results, on our customers and on national, state and local economies; and new risks that may arise due to responses to the pandemic by the government, our customers and us; and other factors disclosed in the Annual Report on Form 10-K for the fiscal year ended March 31, 2020 in the section entitled “Risk Factors,” as such factors may be updated from time to time in our periodic filings with the SEC, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements in this release. All forward-looking statements are based on information currently available to Change Healthcare and are qualified in their entirety by this cautionary statement. The statements herein speak only as of the date such statements were first made. Except to the extent required by law, Change Healthcare assumes no obligation to update any such forward-looking statements or other statements included in this release.

## **NON-GAAP MEASURES DISCLOSURE:**

In the Company’s earnings releases, prepared remarks, conference calls, slide presentations and webcasts, there may be use or discussion of non-GAAP financial measures. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between the comparable GAAP financial measure and each non-GAAP financial measure are included in this presentation after the consolidated financial statements. These non-GAAP financial measures that are calculated and presented on the basis of methodologies other than in accordance with generally accepted accounting principles in the United States of America (“GAAP”). These non-GAAP financial measures should be considered only as supplemental to, and not as superior to, financial measures prepared in accordance with GAAP.

08.06.20


# Overview and Business Update

Neil de Crescenzo  
President and CEO




# Change Healthcare – First Quarter FY21 CEO Summary


## Financial Results Q1 FY2021




## Business Highlights



## New Innovation



# Gradual Recovery in Healthcare Utilization Since Mid-April



08.06.20

# Financial Performance

Fredrik Eliasson  
EVP and Chief Financial Officer



# Q1 FY'21 Performance

In millions except EPU	CH Inc. Q1 FY'21	CH LLC Q1 FY'20	% Change <sup>(2)</sup>
Consolidated Revenue	\$ 694	\$ 856	(18.9%)
Solutions Revenue	648	797	(18.7%)
EBITDA	129	232	(44.3%)
Net Income	(59)	72	(181.6%)
Diluted EPU <sup>(1)</sup>	(0.18)	0.28	(164.5%)
Adjusted EBITDA	197	281	(30.0%)
Adjusted Net Income	81	141	(42.6%)
Adjusted Diluted EPS	0.25	0.56	(54.8%)
Diluted Number of Shares <sup>(1)</sup>	320	253	26.3%

Note 1: Prior to the McKesson exit, common units of Change Healthcare LLC are equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.

Note 2: Percentage change does not reflect rounding of the numbers.

## Q1 FY'21 Business Highlights

- **Solutions Revenue and Adjusted EBITDA include:**
  - New business wins across portfolio more than offset by COVID-19 impact
  - Net YoY revenue and AEBITDA impact from M&A of \$6 million and \$1 million, respectively
  - Continued execution of synergy realization and business optimization
  - Continued investment in R&D and enterprise sales
  - Revenue impacted by \$55 million due to lower deferred revenue as part of fair value adjustments
- **Adjusted Net Income of \$81.2 million or \$0.25 per diluted share**
  - Lower interest expense due to reduction in YoY long-term debt outstanding and higher tax rate
  - Increased integration D&A expense

# Q1 FY'21 Segment Performance

In millions	CH Inc. Q1 FY'21	CH LLC Q1 FY'20	% Change <sup>(2)</sup>
-------------	---------------------	--------------------	----------------------------

## Segment Revenue

S&A	\$ 392	\$ 434	(9.7%)
Network	143	142	0.9%
TES	188	248	(24.2%)
Postage and Elimination <sup>(1)</sup>	27	33	(17.0%)
Purchase Accounting Adj.	(55)	-	-
<b>Total Net Revenue</b>	<b>694</b>	<b>856</b>	<b>(18.9%)</b>

## Segment Adjusted EBITDA - New Methodology

S&A	\$ 144	\$ 177	(18.5%)
Network	71	79	(11.0%)
TES	(18)	25	(169.4%)
Postage and Elimination <sup>(1)</sup>	-	-	-
<b>Total Adjusted EBITDA</b>	<b>197</b>	<b>281</b>	<b>(30.0%)</b>

Note 1: CH-LLC reflect incorporation of new allocation methodology; reconciliation is provided in the appendix.  
Note 2: Percentage change does not reflect rounding of the numbers.

## Q1 FY'21 Segment Highlights

- **S&A: Execution Across Segment**
  - COVID-19 related impact on contingency/renewal-based revenue of approximately (25%)
  - Strength in Payment Accuracy and Decision Support
  - Implementations and new wins in cloud-based EI solution
  - Impact from Connected Analytics sale of ~\$11 million
- **Network: Strength in Data Solutions**
  - Strong growth in Data Solutions; increased market penetration in Medical Network and B2B Payments
  - COVID-19 network volume impact of approximately (20%)
  - Investments to expand market growth for data services, B2B Payments, API's/ Interoperability, and Connected Consumer Health
- **TES: Underlying RCM transformation remains intact**
  - Continued positive trends in RCM win rates and deal size
  - COVID-19 revenue impact approximately (30%) RCM and (20%) CPS
  - Vendor consolidation/outsourcing trends support long term growth



# Q1 FY'21 Cash Generation & Liquidity

- **Free Cash Flow for Q1 FY21 of \$102.3 million<sup>(1)</sup>**
- **Adjusted Free Cash Flow for Q1 FY21 of \$126.6 million<sup>(1)</sup>**
- **Net Debt \$4.9 billion<sup>(2)</sup>; Leverage Ratio 5.2x<sup>(2)</sup>**
- **Liquidity: \$958.3 million**
  - Cash and cash equivalents of approx. \$178.4 million; \$780.0 million undrawn secured credit facility (maturity July 2024) at quarter end
- **No maintenance covenants; earliest debt maturity Term Loan B – March 2024**

Note 1: Includes \$14 million of pass thru funds.

Note 2: Based on Adjusted EBITDA as of June 30, 2020 in accordance with the Credit Agreement.

# Financial Guidance and Assumptions

## Q2 Fiscal 2021 Guidance

(in millions, except per share data<sup>(1)</sup>)

- Solutions revenue between \$670 million to \$690 million; includes impact of \$39 million related to fair value adjustment for deferred revenue
- Adjusted EBITDA between \$180 million to \$190 million; no impact from fair value adjustments
- Adjusted net earnings per share 20 cents to 23 cents

## Q2 Assumptions – Segments

- **Software & Analytics:**
  - 75% of revenue subscription or maintenance – low-single digit growth
  - 25% contingency/renewal-based revenue – negative impact ~ (10%)
- **Network Solutions:**
  - Approximately (10%) decline in network volumes
  - Mid-single digit growth in B2B Payments and high teens growth in Data Solutions
- **Technology-Enabled Services:**
  - Approximately (15%) decline in contingency based RCM revenue, CPS decline of (20%) due to lower volumes, and remaining combined businesses stable

## Full Fiscal Year 2021 Assumptions

- Continued gradual improvement of healthcare utilization throughout the fiscal year
- Expect free cash flow of \$150 million - \$200 million
- CapEx: ~7% of solutions revenue excluding impact of fair value adjustments and integration CapEx
- Integration related OpEx of ~\$80 million and CapEx of ~\$20 million
- Interest expense in the range of \$250 million - \$260 million
- Adjusted effective tax rate: ~25%
- Basic and fully diluted shares outstanding: 320 million<sup>(1)</sup>

Note 1: Diluted shares outstanding includes the impact of the minimum issuable shares attributable to the TEUs and excludes the effect of potential shares that would be antidilutive to Diluted EPS, based on expected GAAP Net Income (Loss) for FY2021.

08.06.20

# Appendix

Q1 FY'21 Financial Statements

Q1 FY'21 and FY'19 Non-GAAP Reconciliations

# Change Healthcare Inc.

## Consolidated Statements of Operations (unaudited and amounts in thousands, except per share and per share amounts)

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc.		Change Healthcare LLC
<b>Revenue:</b>			
Solutions revenue	\$ 648,412	\$ —	\$ 797,072
Postage revenue	45,772	—	58,484
Total revenue	694,184	—	855,556
<b>Operating expenses:</b>			
Cost of operations (exclusive of depreciation and amortization below)	318,542	—	326,947
Research and development	55,734	—	49,339
Sales, marketing, general and administrative	165,474	251	193,273
Customer postage	45,772	—	58,484
Depreciation and amortization	138,541	—	71,316
Accretion and changes in estimate with related parties, net	5,895	—	3,880
Gain on sale of businesses	(28,095)	—	—
<b>Total operating expenses</b>	<b>701,863</b>	<b>251</b>	<b>703,239</b>
<b>Operating income (loss)</b>	<b>(7,679)</b>	<b>(251)</b>	<b>152,317</b>
<b>Non-operating (income) and expense</b>			
Loss from Equity Method Investment in the Joint Venture	—	39,554	—
Interest expense, net	62,667	—	83,406
Contingent consideration	(2,450)	—	(791)
Management fee income	—	(104)	—
Other, net	4,259	—	(3,778)
<b>Total non-operating (income) and expense</b>	<b>64,476</b>	<b>39,450</b>	<b>78,837</b>
<b>Income (loss) before income tax provision (benefit)</b>	<b>(72,155)</b>	<b>(39,701)</b>	<b>73,480</b>
<b>Income tax provision (benefit)</b>	<b>(13,461)</b>	<b>(2,184)</b>	<b>1,565</b>
<b>Net income (loss)</b>	<b>\$ (58,694)</b>	<b>\$ (37,517)</b>	<b>\$ 71,915</b>
<b>Net income (loss) per common share:</b>			
Basic	\$ (0.18)	\$ (0.50)	\$ 0.29
Diluted	\$ (0.18)	\$ (0.50)	\$ 0.28
<b>Weighted average common shares outstanding: <sup>(1)</sup></b>			
Basic	320,052,943	75,474,654	251,469,846
Diluted	320,052,943	75,474,654	253,124,478

<sup>(1)</sup> Prior to the McKesson exit, common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.

# Change Healthcare Inc.

## Consolidated Balance Sheets (unaudited and amounts in thousands, except share and per share amounts)

	June 30, 2020	March 31, 2020
<b>Assets</b>		
<b>Current assets:</b>		
Cash and cash equivalents	\$ 178,351	\$ 410,405
Accounts receivable, net	627,305	740,105
Contract assets, net	122,707	132,704
Prepaid expenses and other current assets	129,309	117,495
Income tax receivable	472	472
<b>Total current assets</b>	<b>1,058,144</b>	<b>1,401,181</b>
Property and equipment, net	203,695	206,196
Operating lease right-of-use assets, net	115,184	—
Goodwill	4,112,880	3,795,325
Intangible assets, net	4,508,247	4,365,806
Investment in business purchase option	—	146,500
Other noncurrent assets, net	265,944	192,372
<b>Total assets</b>	<b>\$ 10,264,094</b>	<b>\$ 10,107,380</b>
<b>Liabilities</b>		
<b>Current liabilities:</b>		
Accounts payable	\$ 59,706	\$ 68,169
Accrued expenses	387,741	390,294
Deferred revenues	314,600	302,313
Due to related parties, net	22,506	20,234
Current portion of long-term debt	28,986	278,779
Current portion of operating lease liabilities	32,753	—
<b>Total current liabilities</b>	<b>846,292</b>	<b>1,059,789</b>
Long-term debt, excluding current portion	5,027,868	4,710,294
Long-term operating lease liabilities	95,514	—
Deferred income tax liabilities	642,102	615,904
Tax receivable agreement obligations to related parties	160,870	177,826
Tax receivable agreement obligation	164,505	164,633
Other long-term liabilities	87,589	93,487
<b>Total liabilities</b>	<b>7,024,740</b>	<b>6,821,933</b>
<b>Commitments and contingencies</b>		
<b>Stockholders' Equity</b>		
Common Stock (par value, \$.001), 9,000,000,000 and 9,000,000,000 shares authorized and 303,769,372 and 303,428,142 shares issued and outstanding at June 30, 2020 and March 31, 2020, respectively	304	303
Preferred stock (par value, \$.001), 900,000,000 and 900,000,000 shares authorized and no shares issued and outstanding at June 30, 2020 and March 31, 2020, respectively	—	—
Additional paid-in capital	4,233,428	4,222,580
Accumulated other comprehensive income (loss)	(5,203)	(7,372)
Accumulated deficit	(989,175)	(930,064)
<b>Total stockholders' equity</b>	<b>3,239,354</b>	<b>3,285,447</b>
<b>Total liabilities and stockholders' equity</b>	<b>\$ 10,264,094</b>	<b>\$ 10,107,380</b>

# Change Healthcare Inc.

## Consolidated Statements of Cash Flows (unaudited and amounts in thousands)

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc.	Change Healthcare LLC	
<b>Cash flows from operating activities:</b>			
Net income (loss)	\$ (58,694)	\$ (37,517)	\$ 71,915
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:			
Loss from Equity Method Investment in the Joint Venture	—	39,554	—
Depreciation and amortization	138,541	—	71,316
Amortization of capitalized software developed for sale	78	—	3,452
Accretion and changes in estimate with related parties, net	5,895	—	3,880
Equity compensation	9,583	—	5,862
Deferred income tax expense (benefit)	(13,845)	(2,184)	1,158
Amortization of debt discount and issuance costs	8,047	—	5,524
Contingent consideration	(2,450)	—	(791)
Gain on sale of businesses	(28,095)	—	—
Other, net	14,618	—	(460)
Changes in operating assets and liabilities:			
Accounts receivable, net	113,470	—	7,748
Contract assets, net	10,013	—	(3,049)
Prepaid expenses and other	(24,632)	—	(16,338)
Accounts payable	(19,244)	—	(33,954)
Accrued expenses and other liabilities	(4,852)	168	19,670
Deferred revenue	20,667	—	(45,194)
Due from the Joint Venture	—	(201)	—
Income taxes receivable	—	180	—
Due to related party, net	—	—	(6,269)
<b>Net cash provided by (used in) operating activities</b>	<b>169,100</b>	<b>—</b>	<b>84,470</b>
<b>Cash flows from investing activities:</b>			
Capitalized expenditures	(66,770)	—	(67,414)
Acquisitions, net of cash acquired	(398,651)	—	—
Proceeds from sale of businesses	28,553	—	—
Other, net	1,039	—	—
<b>Net cash provided by (used in) investing activities</b>	<b>(435,829)</b>	<b>—</b>	<b>(67,414)</b>
<b>Cash flows from financing activities:</b>			
Payments on Revolving Facility	(250,000)	—	—
Proceeds from issuance of Senior Notes	325,000	—	—
Payment of loan costs	(5,364)	—	—
Payments under tax receivable agreements with related parties	(20,691)	—	(27,227)
Receipts (payments) on derivative instruments	(7,364)	—	2,112
Payments on deferred financing obligations	(5,788)	—	—
Repayment of senior amortizing notes	(4,028)	—	—
Proceeds from exercise of equity awards	2,143	—	—
Payments on finance leases	(179)	—	—
Payments on Term Loan Facility	—	—	(12,750)
Other, net	—	—	(759)
<b>Net cash provided by (used in) financing activities</b>	<b>33,729</b>	<b>—</b>	<b>(38,624)</b>
Effect of exchange rate changes on cash and cash equivalents	946	—	60
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(232,054)</b>	<b>—</b>	<b>(21,508)</b>
Cash and cash equivalents at beginning of period	410,405	3,409	48,894
<b>Cash and cash equivalents at end of period</b>	<b>\$ 178,351</b>	<b>\$ 3,409</b>	<b>\$ 27,386</b>

# Change Healthcare Inc.

## Reconciliation of Net Income (Loss) to Adjusted EBITDA

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc. <sup>(1)</sup>		Change Healthcare LLC
<b>Net income (loss)</b>	\$ (58,694)	\$ (37,517)	\$ 71,915
Net interest expense	62,667	—	83,406
Income tax provision (benefit)	(13,461)	(2,184)	1,565
Depreciation and amortization	138,541	—	71,316
Amortization of capitalized software developed for sale	78	—	3,452
<b>EBITDA</b>	<b>129,131</b>	<b>(39,701)</b>	<b>231,654</b>
<b>Adjustments to EBITDA:</b>			
Equity compensation	9,583	—	5,862
Acquisition accounting adjustments	48,540	—	373
Acquisition and divestiture-related costs	5,120	—	658
Integration and related costs	10,358	—	25,725
Strategic initiatives, duplicative and transition costs	5,080	—	3,569
Severance costs	4,704	—	7,170
Accretion and changes in estimate with related parties, net	5,895	—	3,880
Management fees and related costs	—	—	2,648
Impairment of long-lived assets and other	6,313	—	(840)
Gain on sale of business	(28,095)	—	—
Contingent consideration	(2,450)	—	(791)
Other non-routine, net	2,677	—	1,148
EBITDA adjustments	67,725	—	49,402
<b>Adjusted EBITDA</b>	<b>\$ 196,856</b>	<b>\$ —</b>	<b>\$ 281,056</b>

<sup>(1)</sup> Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted EBITDA as a key performance metric, therefore we have not presented a reconciliation to adjusted EBITDA for the three months ended June 30, 2019.

# Change Healthcare Inc.

## Reconciliation of Net Income (Loss) to Adjusted Net Income (Loss)

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc. <sup>(1)</sup>		Change Healthcare LLC
<b>Net income (loss)</b>	\$ (58,694)	\$ (37,517)	\$ 71,915
Amortization expense resulting from acquisition method adjustments	113,024		34,648
EBITDA adjustments	67,725		49,402
Tax effect of EBITDA adjustments and amortization expense	(40,860)		(14,465)
<b>Adjusted net income (loss)</b>	<u>\$ 81,195</u>	<u></u>	<u>\$ 141,500</u>
<b>Adjusted net income (loss) per diluted share <sup>(2)</sup></b>	<u>\$ 0.25</u>	<u></u>	<u>\$ 0.56</u>

<sup>(1)</sup> Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted net income (loss) as a key performance metric, therefore we have not presented a reconciliation to adjusted net income (loss) for the three months ended June 30, 2019.

<sup>(2)</sup> Prior to the McKesson exit, Common units of Change Healthcare LLC were equivalent to the number of outstanding common shares of Change Healthcare Inc. and membership interests of Change Healthcare LLC held by subsidiaries of McKesson.



# Change Healthcare Inc.

## Segment Results

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc. <sup>(1)</sup>		Change Healthcare LLC <sup>(2)</sup>
<b>Segment revenue</b>			
Software and Analytics	\$ 391,589	N/A	\$ 433,821
Network Solutions	142,826	N/A	141,612
Technology-Enabled Services	187,706	N/A	247,513
Postage and Eliminations <sup>(3)</sup>	27,063	N/A	32,610
Purchase Accounting Adjustment <sup>(4)</sup>	(55,000)	N/A	—
Net revenue	<u>\$ 694,184</u>	<u>N/A</u>	<u>\$ 855,556</u>
<b>Segment adjusted EBITDA</b>			
Software and Analytics	\$ 143,932	N/A	\$ 176,501
Network Solutions	70,503	N/A	79,222
Technology-Enabled Services	(17,579)	N/A	25,333
Postage and Eliminations	—	N/A	—
Total adjusted EBITDA	<u>\$ 196,856</u>	<u>N/A</u>	<u>\$ 281,056</u>

<sup>(1)</sup> Prior to the McKesson exit, Change Healthcare Inc. did not have revenues from customers and did not utilize adjusted EBITDA as a key performance metric.

<sup>(2)</sup> The prior year results of Change Healthcare LLC have been retrospectively adjusted to be consistent with the Company's current segment structure and cost allocation methodology.

<sup>(3)</sup> Revenue for Postage and Eliminations includes postage revenue of \$45.8 million for Change Healthcare Inc. for the three months ended June 30, 2020 and \$58.5 million for Change Healthcare LLC for the three months ended June 30, 2019.

<sup>(4)</sup> Amount reflects the impact to deferred revenue resulting from the McKesson exit which reduced revenue recognized during the three months ended June 30, 2020.

# Change Healthcare Inc.

## Reconciliation of Cash Provided by (Used in) Operating Activities to Free Cash Flow and Adjusted Free Cash Flow

	Three Months Ended June 30,		
	2020	2019	2019
	Change Healthcare Inc. <sup>(1)</sup>		Change Healthcare LLC
<b>Cash provided by (used in) operating activities <sup>(2)</sup></b>	\$ 169,100	\$ —	\$ 84,470
Capital expenditures	(66,770)	—	(67,414)
<b>Free cash flow</b>	<u>102,330</u>	<u>—</u>	<u>17,056</u>
<b>Adjustments to free cash flow <sup>(3)</sup>:</b>			
Integration and related costs	10,358		25,725
Strategic initiatives, duplicative and transition costs	5,080		3,569
Severance costs	4,704		7,170
Integration and strategic capital expenditures	4,081		7,247
<b>Adjusted free cash flow</b>	<u>\$ 126,553</u>	<u>—</u>	<u>\$ 60,767</u>

<sup>(1)</sup> Prior to the McKesson exit, Change Healthcare Inc. did not utilize adjusted free cash flow as a key performance metric, therefore we have not presented a reconciliation to adjusted free cash flow for the three months ended June 30, 2019.

<sup>(2)</sup> Includes cash provided by pass-thru funds of \$13.7 million for Change Healthcare Inc. for the three months ended June 30, 2020 and \$12.3 million for Change Healthcare LLC for the three months ended June 30, 2019.

<sup>(3)</sup> All operating costs and integration and strategic capital expenditures are presented on an as-incurred basis.

# Change Healthcare LLC

## Recast Results to Reflect New Allocation Methodology

### SEGMENT ADJUSTED EBITDA (unaudited, amounts in thousands)

	Software and Analytics	Network Solutions	Technology-Enabled Services	Postage and Eliminations	Total
<b>Fiscal Year 2020:</b>					
First Quarter	\$ 176,501	\$ 79,222	\$ 25,333	\$ —	\$ 281,056
Second Quarter	110,993	79,526	27,174	—	217,693
Third Quarter	127,793	87,571	17,262	—	232,626
Fourth Quarter	150,341	85,340	28,677	—	264,358
<b>Total</b>	<b>\$ 565,629</b>	<b>\$ 331,659</b>	<b>\$ 98,445</b>	<b>\$ —</b>	<b>\$ 995,733</b>
<b>Fiscal Year 2019:</b>					
First Quarter	\$ 121,098	\$ 76,852	\$ 29,798	\$ —	\$ 227,749
Second Quarter	117,132	78,775	20,045	—	215,952
Third Quarter	126,416	83,367	24,294	—	234,077
Fourth Quarter	154,434	78,191	24,556	—	257,180
<b>Total</b>	<b>\$ 519,081</b>	<b>\$ 317,185</b>	<b>\$ 98,693</b>	<b>\$ —</b>	<b>\$ 934,958</b>

Note: During the first quarter of fiscal year 2021, the Company decided to allocate all administrative and certain other corporate expenses to the respective reportable segments. This allocation methodology differs from the methodology utilized by the Joint Venture in prior fiscal years. Therefore, the Adjusted EBITDA of the Joint Venture's reportable segments has been retrospectively adjusted for those periods to be consistent with the Company's current allocation methodology.

# CHANGE HEALTHCARE